-
Mashup Score: 7
Resmetirom, a liver-directed, thyroid hormone receptor beta-selective agonist, has recently been approved to treat nonalcoholic steatohepatitis (NASH). This meta-analysis aimed to summarize the efficiency and safety of resmetirom in treating NASH.
Source: www.endocrinepractice.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 2Proton Pump Inhibitors Do Not Affect the Bioavailability of a Novel Liquid Formulation of Levothyroxine - 18 day(s) ago
This study evaluates the impact of a representative proton pump inhibitor (PPI) (omeprazole), administered simultaneously or staggered, on the pharmacokinetics of levothyroxine (LT4) solution (Tirosint-SOL).
Source: www.endocrinepractice.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 12Team-Based Care for Thyroid Cancer: What Is the Role of the Primary Care Physician? - 1 month(s) ago
It is estimated that 43 720 new cases of thyroid cancer will be diagnosed in 2023.1 Owing to advances in diagnosis and treatment, the 5-year relative survival rate for patients is 98.5%. The number of thyroid cancer survivors has been increasing due to increasing incidence, young age at diagnosis, and generally good survival. In fact, thyroid cancer is the third most common cancer among female cancer survivors.2
Source: www.endocrinepractice.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 12Team-Based Care for Thyroid Cancer: What Is the Role of the Primary Care Physician? - 1 month(s) ago
It is estimated that 43 720 new cases of thyroid cancer will be diagnosed in 2023.1 Owing to advances in diagnosis and treatment, the 5-year relative survival rate for patients is 98.5%. The number of thyroid cancer survivors has been increasing due to increasing incidence, young age at diagnosis, and generally good survival. In fact, thyroid cancer is the third most common cancer among female cancer survivors.2
Source: www.endocrinepractice.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 7
In the last decade, new systemic treatment options have been made available for patients with advanced thyroid cancer. However, little is known about the real-world utilization of these systemic therapies.
Source: www.endocrinepractice.orgCategories: General Medicine News, EndocrinologyTweet
In Press at #EndocrinePractice by @deepduttaendo @abm_kamrul et al Role of Resmetirom, a Liver-Directed, #Thyroid Hormone Receptor Beta-Selective Agonist, in Managing Nonalcoholic Steatohepatitis Editorial by Dr Bodnar @Els_ENDO https://t.co/9RZ27Wh52P https://t.co/hxETDTyg1E